Literature DB >> 17982491

Virus-mediated oncolysis induces danger signal and stimulates cytotoxic T-lymphocyte activity via proteasome activator upregulation.

Y Endo1, R Sakai, M Ouchi, H Onimatsu, M Hioki, S Kagawa, F Uno, Y Watanabe, Y Urata, N Tanaka, T Fujiwara.   

Abstract

Dendritic cells (DCs) are the most potent antigen-presenting cells and acquire cellular antigens and danger signals from dying cells to initiate antitumor immune responses via direct cell-to-cell interaction and cytokine production. The optimal forms of tumor cell death for priming DCs for the release of danger signals are not fully understood. OBP-301 (Telomelysin) is a telomerase-specific replication-competent adenovirus that induces selective E1 expression and exclusively kills human cancer cells. Here, we show that OBP-301 replication produced the endogenous danger signaling molecule, uric acid, in infected human tumor cells, which in turn stimulated DCs to produce interferon-gamma (IFN-gamma) and interleukin 12 (IL-12). Subsequently, IFN-gamma release upregulated the endogenous expression of the proteasome activator PA28 in tumor cells and resulted in the induction of cytotoxic T-lymphocytes. Our data suggest that virus-mediated oncolysis might be the effective stimulus for immature DCs to induce specific activity against human cancer cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17982491     DOI: 10.1038/sj.onc.1210884

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  36 in total

1.  Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors.

Authors:  Nobuhiro Nishio; Iulia Diaconu; Hao Liu; Vincenzo Cerullo; Ignazio Caruana; Valentina Hoyos; Lisa Bouchier-Hayes; Barbara Savoldo; Gianpietro Dotti
Journal:  Cancer Res       Date:  2014-07-24       Impact factor: 12.701

Review 2.  [Combination of Oncolytic Virotherapy and CAR T/NK Cell Therapy for the Treatment of Cancer].

Authors:  G V Kochneva; G F Sivolobova; A V Tkacheva; A A Gorchakov; S V Kulemzin
Journal:  Mol Biol (Mosk)       Date:  2020 Jan-Feb

Review 3.  Changing faces in virology: the dutch shift from oncogenic to oncolytic viruses.

Authors:  Zineb Belcaid; Martine L M Lamfers; Victor W van Beusechem; Rob C Hoeben
Journal:  Hum Gene Ther       Date:  2014-09-17       Impact factor: 5.695

4.  Immunogenic cell death by oncolytic herpes simplex virus type 1 in squamous cell carcinoma cells.

Authors:  A Takasu; A Masui; M Hamada; T Imai; S Iwai; Y Yura
Journal:  Cancer Gene Ther       Date:  2016-03-18       Impact factor: 5.987

5.  Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody.

Authors:  Nobuhiko Kanaya; Shinji Kuroda; Yoshihiko Kakiuchi; Kento Kumon; Tomoko Tsumura; Masashi Hashimoto; Toshiaki Morihiro; Tetsushi Kubota; Katsuyuki Aoyama; Satoru Kikuchi; Masahiko Nishizaki; Shunsuke Kagawa; Hiroshi Tazawa; Hiroyuki Mizuguchi; Yasuo Urata; Toshiyoshi Fujiwara
Journal:  Mol Ther       Date:  2020-01-10       Impact factor: 11.454

6.  Maraba virus as a potent oncolytic vaccine vector.

Authors:  Jonathan G Pol; Liang Zhang; Byram W Bridle; Kyle B Stephenson; Julien Rességuier; Stephen Hanson; Lan Chen; Natasha Kazdhan; Jonathan L Bramson; David F Stojdl; Yonghong Wan; Brian D Lichty
Journal:  Mol Ther       Date:  2013-10-25       Impact factor: 11.454

7.  Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles.

Authors:  Han Hsi Wong; Nicholas R Lemoine; Yaohe Wang
Journal:  Viruses       Date:  2010-01       Impact factor: 5.818

8.  Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer.

Authors:  Assia L Angelova; Svitlana P Grekova; Anette Heller; Olga Kuhlmann; Esther Soyka; Thomas Giese; Marc Aprahamian; Gaétan Bour; Sven Rüffer; Celina Cziepluch; Laurent Daeffler; Jean Rommelaere; Jens Werner; Zahari Raykov; Nathalia A Giese
Journal:  J Virol       Date:  2014-02-26       Impact factor: 5.103

Review 9.  Oncolytic viruses: a novel form of immunotherapy.

Authors:  Robin J Prestwich; Kevin J Harrington; Hardev S Pandha; Richard G Vile; Alan A Melcher; Fiona Errington
Journal:  Expert Rev Anticancer Ther       Date:  2008-10       Impact factor: 4.512

Review 10.  The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon.

Authors:  Robin J Prestwich; Fiona Errington; Rosa M Diaz; Hardev S Pandha; Kevin J Harrington; Alan A Melcher; Richard G Vile
Journal:  Hum Gene Ther       Date:  2009-10       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.